George Clinical, Omico to evolve oncology study enrolment via genomic profiling in Australia

KUALA LUMPUR, June 16 -- George Clinical, a global scientifically-backed clinical research organisation, and Omico, an Australian-based not-for-profit national precision oncology platform, have aligned to revolutionise oncology clinical trial access for patients and improve the efficiency of study enrolment.

The two organisations began collaborating late last year and announced the joint effort during the 2021 ASCO Annual Meeting, according to a statement.

“Helping clinicians and cancer centres target the right patients for the right clinical trials will not only accelerate study enrolment, it will help patients get quicker access to the studies most relevant to their treatment needs,” said Chief Medical Officer Maria Ali.

“We are excited this novel relationship with Omico can be a game changer for sponsors globally and patients locally.”

Genomic profiling is changing cancer medicine, enabling mapping of the mutational circuitry of cancers.

Dozens of highly effective therapies have changed treatment options for many cancers and received regulatory approval. This evolution has driven the development of large-scale genomic profiling programmes linked to biomarker-dependent therapeutic trials.

In Australia, a national precision oncology platform to enable large-scale genomic screening of cancer patients has been developed through the innovative work of Omico.

The George Clinical collaboration with Omico looks to harness the paradigm-shifting potential of this platform to change the way oncology trials are conducted in Australia.

George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.

More details at https://www.georgeclinical.com.

-- BERNAMA